Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Brexogen General Information
Brexogen is currently conducting Phase 1 clinical trials for severe atopic dermatitis treatment in the U.S. with their exosome-based therapeutics. They have multiple programs in development, including treatments for myocardial infarction and metabolic diseases requiring regeneration.
Contact Information
Drug Pipeline
BRE-AD01
Phase 1Key Partnerships
BMI Korea (technology transfer and licensing agreement signed in February 2025)
Brexogen Funding
No funding data available
To view Brexogen's complete valuation and funding history, request access »